Clinical Trials in Ontario
Below is a list of planned or ongoing clinical trials in Ontario provided for information purposes. Please read the information regarding inclusion and exclusion criteria closely before contacting investigators for enrolment. Only contact if you meet their criteria. Other trials can be found at ClinicalTrials.gov and the Stanford University Coronavirus Antiviral Research Database
CONCOR-1
CONCOR-1
Study Design & Outcomes
Study Type
RCT
Study Arms
1) COVID-19 convalescent plasma + standard care
2) Standard care
2:1 Enrolment (Treatment:Control)
Primary Outcome
In-hospital mortality
Inclusion & Exclusion Criteria
Inclusion
Age >/= 16 years
Admitted to the hospital with confirmed COVID-19 illness
Receiving supplemental oxygen for COVID-19 illness
500mL ABO-compatible convalescent plasma available
Exclusion
Please contact investigators for details
RAPID COVID COAG
RAPID COVID COAG
Study Design & Outcomes
Study Type
Open-Label RCT
Study Arms
1) LMWH DVT prophylaxis
2) LMWH therapeutic
Primary Outcome
composite of mortality and respiratory failure
Inclusion & Exclusion Criteria
Inclusion
D-dimer 2X upper limit of normal
Hospitalized (Not in ICU)
Receiving Supplemental Oxygen
Exclusion
Please contact investigators for details
Michelle Sholzberg
COVID-19 PEP
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP)
Study Design & Outcomes
Study Type
RCT
Study Arms
Hydroxychloroquine vs placebo
Primary Outcome
preventing COIVD-19 and/or decreasing severity
Inclusion & Exclusion Criteria
Inclusion
Adults >18 years:
- with symptoms beginning in the past 4 days and a confirmed diagnosis of COVID-19 via testing, and are self-isolating at home (not in hospital); OR
- healthcare worker with symptoms for the last 4 days or less and had contact with a patient with confirmed COVID-19 in the past 14 days; OR - who are a household member without symptoms exposed in the last 4 days to a person with known COVID-19; OR
- who are a healthcare without symptoms with a moderate to high risk contact in the last 4 days to a patient with known COVID-19
Exclusion
Please contact investigators for details
Todd Lee
enrollment via IPAC and Toronto Public Health contact tracing
CATCO
Canadian Treatments for COVID-19
Study Design & Outcomes
Study Type
Open-Label RCT
Study Arms
1) Remdesivir
2) Hydroxychloroquine
3) Kaletra [lopinavir/ritonavir]
4) Supportive care
5) Kaletra + IFN-B1a + Optimized Supportive care* (*not in Canada)
Primary Outcome
In-Hospital Mortality
Inclusion & Exclusion Criteria
Inclusion
- SARCS-CoV2 infection
Exclusion
Please contact investigators for details
Srinivas Murthy